|Mr. Anthony J. Hunt||CEO, Pres, Director & Member of Scientific Advisory Board||985k||488.68k||1964|
|Mr. Jon K. Snodgres||CFO & Sec.||427.75k||1.15M||1966|
|Mr. Ralf Kuriyel||Sr. VP of R&D||504.2k||N/A||1959|
|Mr. Steve Curran||VP of Global Operations||N/A||N/A||N/A|
|Ms. Sondra S. Newman||Global Head of Investor Relations||N/A||N/A||N/A|
Repligen Corporation develops and commercializes bioprocessing technologies and systems that are used in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA kits, which are analytical test kits to quantitate the proteins and growth factors; chromatography resins under the CaptivA brand; and liquid chromatography products under the Spectra/Chrom brand. In addition, the company offers filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber module-bag-tubing sets. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE and FlowVPE brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. It has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands; and Sartorius Stedim Biotech to create novel perfusion-enabled bioreactors. Repligen Corporation was founded in 1981 and is headquartered in Waltham, Massachusetts.
Repligen Corporation’s ISS Governance QualityScore as of December 4, 2019 is 6. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 1; Compensation: 10.